Physician profile
Benjamin Lev Solomon
NPI 1518209485
$7,824.43
in general payments reported to CMS, 2019-2025
31 companies · $4,773 in 2025
The $4,773 reported for 2025 was more than what 81% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $16.05 · 2022: $372 · 2023: $1,747 · 2024: $917 · 2025: $4,773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,760 · Food and Beverage: $2,520 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,759.75 |
| Food and Beverage | $2,519.88 |
| Education | $156.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $3,570.44 | 2021-2025 | Datroway, Enhertu, Injectafer |
| Janssen Biotech, INC. | $1,006.05 | 2022-2025 | Darzalex, Rybrevant, Tecvayli |
| Geron Corporation | $780.00 | 2025 | Rytelo |
| Novartis Pharmaceuticals Corporation | $305.20 | 2023-2025 | |
| Pfizer INC. | $291.31 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $245.85 | 2023-2025 | Imfinzi, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $240.24 | 2022-2025 | Opdivo, Opdualag |
| Eisai INC. | $158.25 | 2022-2025 | |
| Glaxosmithkline, LLC. | $152.41 | 2023-2025 | Jemperli, Zejula, Ojjaara |
| Incyte Corporation | $120.79 | 2025 | Jakafi, Niktimvo |
| Emd Serono, INC. | $113.94 | 2023-2025 | Bavencio |
| Gilead Sciences, INC. | $99.78 | 2024-2025 | Trodelvy |
| Genmab U.S., INC. | $84.55 | 2023-2025 | Tivdak |
| Array Biopharma INC | $73.41 | 2025 | Braftovi, Lorbrena, Tukysa |
| Beigene USA, INC. | $70.92 | 2022-2023 | Brukinsa |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $55.27 | 2024 | Tavalisse, Rezlidhia |
| Merck Sharp & Dohme LLC | $51.20 | 2022-2025 | Keytruda, Keytruda Qlex |
| Ipsen Biopharmaceuticals, INC | $49.99 | 2024 | Somatuline Depot, Onivyde |
| Genentech USA, INC. | $43.25 | 2022-2023 | Tecentriq |
| Celgene Corporation | $41.58 | 2022-2025 | Reblozyl |
| Azurity Pharmaceuticals, INC. | $37.95 | 2025 | Danziten |
| Genzyme Corporation | $36.14 | 2023 | |
| Tersera Therapeutics LLC | $28.91 | 2025 | Zoladex |
| Pharmaessentia USA Corporation | $28.14 | 2024 | Besremi |
| Tempus Ai, INC | $25.07 | 2025 | Xt Cdx |
| Astellas Pharma US INC | $21.35 | 2025 | Xtandi |
| Recordati_rare_diseases_inc. | $20.93 | 2025 | Enjaymo |
| Puma Biotechnology, INC. | $19.63 | 2025 | |
| Stemline Therapeutics INC. | $18.47 | 2024 | Orserdu |
| Verity Pharmaceuticals INC. | $17.57 | 2025 | Trelstar |
| Novocure INC. | $15.84 | 2025 | Optune Gio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Solomon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.